SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results And Updated Financial Guidance

  TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected RECIST responses observed with TPST-1120 combined with

Benzinga · 06/09/2022 08:03

 

  • TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected

  • RECIST responses observed with TPST-1120 combined with anti-PD1 therapy in patients who previously progressed on anti-PD1/PDL1 therapy
  • Potential biomarker for patient responsiveness to TPST-1120 identified and will be further explored
  • TPST-1120 demonstrated the ability to reprogram the tumor microenvironment (TME) in a tumor type that is refractory to anti-PD1 with low tumor mutation burden
  • TPST-1120 is also in an ongoing randomized global Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in first-line patients with hepatocellular carcinoma
  • Cash runway into 2024